For Immediate Release
Media Contact: Todd Dvorak
(208) 334-4112

Date: November 5, 2015

Astrazeneca Pays $46.5 Million, Cephalon $7.5 Million in Nationwide Civil Settlements

(Boise) - Attorney General Lawrence Wasden announced that Idaho has joined with all 50 states and the federal government to settle allegations that AstraZeneca Pharmaceuticals, LP and Cephalon, Inc., overcharged the state Medicaid programs for prescription drugs.

Idaho will receive $11,095 from Cephalon and $32,195 from Astrazeneca in restitution and other recovery as its part of the settlements.

Specifically, these settlements resolve allegations that AstraZeneca and Cephalon underpaid drug rebates owed to the states. Under a federal law known as the Medicaid Drug Rebate Program, drug manufacturers must periodically return a portion of the amount paid by state Medicaid programs for the manufacturers’ drugs. The rebate program is designed to ensure that states pay competitive prices for drugs, and the rebates for a manufacturer’s drugs are calculated based on a percentage of the average prices drug wholesalers pay for each of the drugs. This average price, which the manufacturer reports to the federal government, is known as the Average Manufacturer’s Price or “AMP”. The greater the AMP reported by the manufacturer, the greater the rebate the manufacturer must pay for that drug.

The investigation resulted from an action filed in the United States District Court for the Eastern District of Pennsylvania under the federal False Claims Act and various state false claims statutes. AstraZeneca, a London and Delaware-based pharmaceutical manufacturer, has paid the states and the federal government $46.5 million to resolve allegations against the company. Cephalon, a Pennsylvania-based subsidiary of Teva Pharmaceuticals Industries, Ltd., has paid the states and the federal government $7.5 million to settle similar allegations.

The whistleblower’s complaint alleged that AstraZeneca and Cephalon improperly treated certain fees paid to wholesalers as “discounts,” and that the effect of this accounting practice was to falsely decrease the AMP the companies reported to the federal government, improperly decreasing the rebates paid to the states.

A National Association of Medicaid Fraud Control Units (NAMFCU) Team participated in the investigation and conducted the settlement negotiations with AstraZeneca and Cephalon on behalf of the states.

- End -

News by Year:
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003